A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube
To determine the safety and efficacy of the novel combination of docetaxel, oxaliplatin, and bevacizumab as first-line treatment of advanced cancer of the ovary, peritoneum or fallopian tube after initial debulking surgery.
Gespeichert in:
| Autor*in: |
Herzog, Thomas J. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014 |
|---|
| Umfang: |
9 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes - Gibson, Diane M. ELSEVIER, 2017, an international journal : official publication of the Society of Gynecologic Oncologists [u.a.], Orlando, Fla |
|---|---|
| Übergeordnetes Werk: |
volume:132 ; year:2014 ; number:3 ; pages:517-525 ; extent:9 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ygyno.2014.01.035 |
|---|
| Katalog-ID: |
ELV011973331 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV011973331 | ||
| 003 | DE-627 | ||
| 005 | 20230623093653.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180602s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ygyno.2014.01.035 |2 doi | |
| 028 | 5 | 2 | |a GBVA2014001000007.pica |
| 035 | |a (DE-627)ELV011973331 | ||
| 035 | |a (ELSEVIER)S0090-8258(14)00095-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.11 |2 bkl | ||
| 100 | 1 | |a Herzog, Thomas J. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube |
| 264 | 1 | |c 2014 | |
| 300 | |a 9 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a To determine the safety and efficacy of the novel combination of docetaxel, oxaliplatin, and bevacizumab as first-line treatment of advanced cancer of the ovary, peritoneum or fallopian tube after initial debulking surgery. | ||
| 700 | 1 | |a Monk, Bradley J. |4 oth | |
| 700 | 1 | |a Rose, Peter G. |4 oth | |
| 700 | 1 | |a Braly, Patricia |4 oth | |
| 700 | 1 | |a Hines, Jeffrey F. |4 oth | |
| 700 | 1 | |a Bell, Maria C. |4 oth | |
| 700 | 1 | |a Wenham, Robert M. |4 oth | |
| 700 | 1 | |a Secord, Angeles Alvarez |4 oth | |
| 700 | 1 | |a Roman, Lynda D. |4 oth | |
| 700 | 1 | |a Einstein, Mark H. |4 oth | |
| 700 | 1 | |a Drake, Richard D. |4 oth | |
| 700 | 1 | |a Childs, Barrett H. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Academic Press |a Gibson, Diane M. ELSEVIER |t Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes |d 2017 |d an international journal : official publication of the Society of Gynecologic Oncologists [u.a.] |g Orlando, Fla |w (DE-627)ELV000708127 |
| 773 | 1 | 8 | |g volume:132 |g year:2014 |g number:3 |g pages:517-525 |g extent:9 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ygyno.2014.01.035 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.11 |j Präventivmedizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 132 |j 2014 |e 3 |h 517-525 |g 9 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
t j h tj tjh |
|---|---|
| matchkey_str |
herzogthomasjmonkbradleyjrosepetergbraly:2014----:paeiraooailtnoeaeadeaiuaafrtiehrpoavnecneot |
| hierarchy_sort_str |
2014 |
| bklnumber |
44.11 |
| publishDate |
2014 |
| allfields |
10.1016/j.ygyno.2014.01.035 doi GBVA2014001000007.pica (DE-627)ELV011973331 (ELSEVIER)S0090-8258(14)00095-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.11 bkl Herzog, Thomas J. verfasserin aut A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube 2014 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier To determine the safety and efficacy of the novel combination of docetaxel, oxaliplatin, and bevacizumab as first-line treatment of advanced cancer of the ovary, peritoneum or fallopian tube after initial debulking surgery. Monk, Bradley J. oth Rose, Peter G. oth Braly, Patricia oth Hines, Jeffrey F. oth Bell, Maria C. oth Wenham, Robert M. oth Secord, Angeles Alvarez oth Roman, Lynda D. oth Einstein, Mark H. oth Drake, Richard D. oth Childs, Barrett H. oth Enthalten in Academic Press Gibson, Diane M. ELSEVIER Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes 2017 an international journal : official publication of the Society of Gynecologic Oncologists [u.a.] Orlando, Fla (DE-627)ELV000708127 volume:132 year:2014 number:3 pages:517-525 extent:9 https://doi.org/10.1016/j.ygyno.2014.01.035 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.11 Präventivmedizin VZ AR 132 2014 3 517-525 9 045F 610 |
| spelling |
10.1016/j.ygyno.2014.01.035 doi GBVA2014001000007.pica (DE-627)ELV011973331 (ELSEVIER)S0090-8258(14)00095-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.11 bkl Herzog, Thomas J. verfasserin aut A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube 2014 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier To determine the safety and efficacy of the novel combination of docetaxel, oxaliplatin, and bevacizumab as first-line treatment of advanced cancer of the ovary, peritoneum or fallopian tube after initial debulking surgery. Monk, Bradley J. oth Rose, Peter G. oth Braly, Patricia oth Hines, Jeffrey F. oth Bell, Maria C. oth Wenham, Robert M. oth Secord, Angeles Alvarez oth Roman, Lynda D. oth Einstein, Mark H. oth Drake, Richard D. oth Childs, Barrett H. oth Enthalten in Academic Press Gibson, Diane M. ELSEVIER Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes 2017 an international journal : official publication of the Society of Gynecologic Oncologists [u.a.] Orlando, Fla (DE-627)ELV000708127 volume:132 year:2014 number:3 pages:517-525 extent:9 https://doi.org/10.1016/j.ygyno.2014.01.035 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.11 Präventivmedizin VZ AR 132 2014 3 517-525 9 045F 610 |
| allfields_unstemmed |
10.1016/j.ygyno.2014.01.035 doi GBVA2014001000007.pica (DE-627)ELV011973331 (ELSEVIER)S0090-8258(14)00095-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.11 bkl Herzog, Thomas J. verfasserin aut A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube 2014 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier To determine the safety and efficacy of the novel combination of docetaxel, oxaliplatin, and bevacizumab as first-line treatment of advanced cancer of the ovary, peritoneum or fallopian tube after initial debulking surgery. Monk, Bradley J. oth Rose, Peter G. oth Braly, Patricia oth Hines, Jeffrey F. oth Bell, Maria C. oth Wenham, Robert M. oth Secord, Angeles Alvarez oth Roman, Lynda D. oth Einstein, Mark H. oth Drake, Richard D. oth Childs, Barrett H. oth Enthalten in Academic Press Gibson, Diane M. ELSEVIER Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes 2017 an international journal : official publication of the Society of Gynecologic Oncologists [u.a.] Orlando, Fla (DE-627)ELV000708127 volume:132 year:2014 number:3 pages:517-525 extent:9 https://doi.org/10.1016/j.ygyno.2014.01.035 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.11 Präventivmedizin VZ AR 132 2014 3 517-525 9 045F 610 |
| allfieldsGer |
10.1016/j.ygyno.2014.01.035 doi GBVA2014001000007.pica (DE-627)ELV011973331 (ELSEVIER)S0090-8258(14)00095-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.11 bkl Herzog, Thomas J. verfasserin aut A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube 2014 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier To determine the safety and efficacy of the novel combination of docetaxel, oxaliplatin, and bevacizumab as first-line treatment of advanced cancer of the ovary, peritoneum or fallopian tube after initial debulking surgery. Monk, Bradley J. oth Rose, Peter G. oth Braly, Patricia oth Hines, Jeffrey F. oth Bell, Maria C. oth Wenham, Robert M. oth Secord, Angeles Alvarez oth Roman, Lynda D. oth Einstein, Mark H. oth Drake, Richard D. oth Childs, Barrett H. oth Enthalten in Academic Press Gibson, Diane M. ELSEVIER Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes 2017 an international journal : official publication of the Society of Gynecologic Oncologists [u.a.] Orlando, Fla (DE-627)ELV000708127 volume:132 year:2014 number:3 pages:517-525 extent:9 https://doi.org/10.1016/j.ygyno.2014.01.035 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.11 Präventivmedizin VZ AR 132 2014 3 517-525 9 045F 610 |
| allfieldsSound |
10.1016/j.ygyno.2014.01.035 doi GBVA2014001000007.pica (DE-627)ELV011973331 (ELSEVIER)S0090-8258(14)00095-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 44.11 bkl Herzog, Thomas J. verfasserin aut A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube 2014 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier To determine the safety and efficacy of the novel combination of docetaxel, oxaliplatin, and bevacizumab as first-line treatment of advanced cancer of the ovary, peritoneum or fallopian tube after initial debulking surgery. Monk, Bradley J. oth Rose, Peter G. oth Braly, Patricia oth Hines, Jeffrey F. oth Bell, Maria C. oth Wenham, Robert M. oth Secord, Angeles Alvarez oth Roman, Lynda D. oth Einstein, Mark H. oth Drake, Richard D. oth Childs, Barrett H. oth Enthalten in Academic Press Gibson, Diane M. ELSEVIER Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes 2017 an international journal : official publication of the Society of Gynecologic Oncologists [u.a.] Orlando, Fla (DE-627)ELV000708127 volume:132 year:2014 number:3 pages:517-525 extent:9 https://doi.org/10.1016/j.ygyno.2014.01.035 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.11 Präventivmedizin VZ AR 132 2014 3 517-525 9 045F 610 |
| language |
English |
| source |
Enthalten in Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes Orlando, Fla volume:132 year:2014 number:3 pages:517-525 extent:9 |
| sourceStr |
Enthalten in Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes Orlando, Fla volume:132 year:2014 number:3 pages:517-525 extent:9 |
| format_phy_str_mv |
Article |
| bklname |
Präventivmedizin |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes |
| authorswithroles_txt_mv |
Herzog, Thomas J. @@aut@@ Monk, Bradley J. @@oth@@ Rose, Peter G. @@oth@@ Braly, Patricia @@oth@@ Hines, Jeffrey F. @@oth@@ Bell, Maria C. @@oth@@ Wenham, Robert M. @@oth@@ Secord, Angeles Alvarez @@oth@@ Roman, Lynda D. @@oth@@ Einstein, Mark H. @@oth@@ Drake, Richard D. @@oth@@ Childs, Barrett H. @@oth@@ |
| publishDateDaySort_date |
2014-01-01T00:00:00Z |
| hierarchy_top_id |
ELV000708127 |
| dewey-sort |
3610 |
| id |
ELV011973331 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV011973331</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623093653.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ygyno.2014.01.035</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014001000007.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV011973331</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0090-8258(14)00095-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.11</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Herzog, Thomas J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">To determine the safety and efficacy of the novel combination of docetaxel, oxaliplatin, and bevacizumab as first-line treatment of advanced cancer of the ovary, peritoneum or fallopian tube after initial debulking surgery.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Monk, Bradley J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rose, Peter G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Braly, Patricia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hines, Jeffrey F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bell, Maria C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wenham, Robert M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Secord, Angeles Alvarez</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roman, Lynda D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Einstein, Mark H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Drake, Richard D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Childs, Barrett H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Academic Press</subfield><subfield code="a">Gibson, Diane M. ELSEVIER</subfield><subfield code="t">Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes</subfield><subfield code="d">2017</subfield><subfield code="d">an international journal : official publication of the Society of Gynecologic Oncologists [u.a.]</subfield><subfield code="g">Orlando, Fla</subfield><subfield code="w">(DE-627)ELV000708127</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:132</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:517-525</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ygyno.2014.01.035</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.11</subfield><subfield code="j">Präventivmedizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">132</subfield><subfield code="j">2014</subfield><subfield code="e">3</subfield><subfield code="h">517-525</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Herzog, Thomas J. |
| spellingShingle |
Herzog, Thomas J. ddc 610 bkl 44.11 A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube |
| authorStr |
Herzog, Thomas J. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV000708127 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.11 bkl A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube |
| topic |
ddc 610 bkl 44.11 |
| topic_unstemmed |
ddc 610 bkl 44.11 |
| topic_browse |
ddc 610 bkl 44.11 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
b j m bj bjm p g r pg pgr p b pb j f h jf jfh m c b mc mcb r m w rm rmw a a s aa aas l d r ld ldr m h e mh mhe r d d rd rdd b h c bh bhc |
| hierarchy_parent_title |
Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes |
| hierarchy_parent_id |
ELV000708127 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV000708127 |
| title |
A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube |
| ctrlnum |
(DE-627)ELV011973331 (ELSEVIER)S0090-8258(14)00095-X |
| title_full |
A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube |
| author_sort |
Herzog, Thomas J. |
| journal |
Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes |
| journalStr |
Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
517 |
| author_browse |
Herzog, Thomas J. |
| container_volume |
132 |
| physical |
9 |
| class |
610 610 DE-600 610 VZ 44.11 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Herzog, Thomas J. |
| doi_str_mv |
10.1016/j.ygyno.2014.01.035 |
| dewey-full |
610 |
| title_sort |
a phase ii trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube |
| title_auth |
A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube |
| abstract |
To determine the safety and efficacy of the novel combination of docetaxel, oxaliplatin, and bevacizumab as first-line treatment of advanced cancer of the ovary, peritoneum or fallopian tube after initial debulking surgery. |
| abstractGer |
To determine the safety and efficacy of the novel combination of docetaxel, oxaliplatin, and bevacizumab as first-line treatment of advanced cancer of the ovary, peritoneum or fallopian tube after initial debulking surgery. |
| abstract_unstemmed |
To determine the safety and efficacy of the novel combination of docetaxel, oxaliplatin, and bevacizumab as first-line treatment of advanced cancer of the ovary, peritoneum or fallopian tube after initial debulking surgery. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
3 |
| title_short |
A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube |
| url |
https://doi.org/10.1016/j.ygyno.2014.01.035 |
| remote_bool |
true |
| author2 |
Monk, Bradley J. Rose, Peter G. Braly, Patricia Hines, Jeffrey F. Bell, Maria C. Wenham, Robert M. Secord, Angeles Alvarez Roman, Lynda D. Einstein, Mark H. Drake, Richard D. Childs, Barrett H. |
| author2Str |
Monk, Bradley J. Rose, Peter G. Braly, Patricia Hines, Jeffrey F. Bell, Maria C. Wenham, Robert M. Secord, Angeles Alvarez Roman, Lynda D. Einstein, Mark H. Drake, Richard D. Childs, Barrett H. |
| ppnlink |
ELV000708127 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.ygyno.2014.01.035 |
| up_date |
2024-07-06T21:12:06.556Z |
| _version_ |
1803865635219832832 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV011973331</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623093653.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ygyno.2014.01.035</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014001000007.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV011973331</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0090-8258(14)00095-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.11</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Herzog, Thomas J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">To determine the safety and efficacy of the novel combination of docetaxel, oxaliplatin, and bevacizumab as first-line treatment of advanced cancer of the ovary, peritoneum or fallopian tube after initial debulking surgery.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Monk, Bradley J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rose, Peter G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Braly, Patricia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hines, Jeffrey F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bell, Maria C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wenham, Robert M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Secord, Angeles Alvarez</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roman, Lynda D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Einstein, Mark H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Drake, Richard D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Childs, Barrett H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Academic Press</subfield><subfield code="a">Gibson, Diane M. ELSEVIER</subfield><subfield code="t">Frequency and predictors of missed visits to primary care and eye care providers for annually recommended diabetes preventive care services over a two-year period among U.S. adults with diabetes</subfield><subfield code="d">2017</subfield><subfield code="d">an international journal : official publication of the Society of Gynecologic Oncologists [u.a.]</subfield><subfield code="g">Orlando, Fla</subfield><subfield code="w">(DE-627)ELV000708127</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:132</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:517-525</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ygyno.2014.01.035</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.11</subfield><subfield code="j">Präventivmedizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">132</subfield><subfield code="j">2014</subfield><subfield code="e">3</subfield><subfield code="h">517-525</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.399398 |